Preview Mode Links will not work in preview mode

This Week in Cardiology

Jan 7, 2022

Causes of sudden death, inclisiran, DOAC choices, and alcohol and VT/VF are the topics discussed by John Mandrola, MD, in this week’s podcast.

To read a partial transcript or to comment, visit:

I – Causes of Sudden Death

- Cardiac Device Interrogation After Death 'Richly Informative'

- Postmortem Interrogation of Cardiac Implantable Electronic Devices: A 15-Year Experience

- Sudden Death in Patients With Cardiac Implantable Electronic Devices

- Cardiac Implantable Electronic Device Interrogation at Forensic Autopsy

II – Inclisiran

- FDA Approves First-in-Class Inclisiran to Lower LDL-C

- ORION: Inclisiran Phase 3 Trials Published

- Meta-Analysis of Inclisiran for the Treatment of Hypercholesterolemia

- Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease

- Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome

III – DOAC Choice

- Apixaban: The 'Anticoagulant of Choice' for AF

- Association of Rivaroxaban vs Apixaban With Major Ischemic or Hemorrhagic Events in Patients With Atrial Fibrillation

IV – Alcohol and VT/VF and SCD

- Some Good News on Alcohol and 'Holiday Heart Syndrome'

- Alcohol consumption and risk of ventricular arrhythmias and sudden cardiac death: An observational study of 408,712 individuals

You may also like:

Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine

The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.

Questions or feedback, please contact